Literature DB >> 30314681

Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles.

Bhaskar Venkata Kameswara Subrahmanya Lakkakula1, Batoul Farran2, Saikrishna Lakkakula3, Sujatha Peela4, Nagendra Sastry Yarla5, Pallaval Veera Bramhachari6, Mohammad Amjad Kamal7, Madhu Sudhana Saddala8, Ganji Purnachandra Nagaraju9.   

Abstract

Pancreatic cancer (PC) is an aggressive carcinoma and the fourth cause of cancer deaths in Western countries. Although surgery is the most effective therapeutic option for PC, the management of unresectable, locally advanced disease is highly challenging. Our improved understanding of pancreatic tumor biology and associated pathways has led to the development of various treatment modalities that can control the metastatic spread of PC. This review intends to present trials of small molecule tyrosine kinase inhibitors (TKIs) in PC management and the troubles encountered due to inevitable acquired resistance to TKIs.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical trials; Pancreatic carcinoma; Resistance; Targeted therapies; Tyrosine kinase inhibitors

Mesh：

Substances：

Year:  2018        PMID： 30314681     DOI： 10.1016/j.semcancer.2018.09.011

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN： 1044-579X            Impact factor:   15.707


  7 in total

1.  A new era: tumor microenvironment in chemoresistance of pancreatic cancer.

Authors:  Xueping Zhao; Zongze Li; Zongting Gu
Journal:  J Cancer Sci Clin Ther       Date:  2022-02-15

Review 2.  Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease.

Authors:  Christopher Gromisch; Motaz Qadan; Mariana Albuquerque Machado; Kebin Liu; Yolonda Colson; Mark W Grinstaff
Journal:  Cancer Res       Date:  2020-03-27       Impact factor: 12.701

3.  Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.

Authors:  Austin R Dosch; Xizi Dai; Michelle L Reyzer; Siddharth Mehra; Supriya Srinivasan; Brent A Willobee; Deukwoo Kwon; Nilesh Kashikar; Richard Caprioli; Nipun B Merchant; Nagaraj S Nagathihalli
Journal:  Mol Cancer Res       Date:  2020-01-16       Impact factor: 5.852

Review 4.  Update on current pancreatic treatments: from molecular pathways to treatment.

Authors:  Konstantinos Sapalidis; Christoforos Kosmidis; Varvara Funtanidou; Athanasios Katsaounis; Amastasios Barmpas; Georgios Koimtzis; Stylianos Mantalobas; Vyron Alexandrou; Zoi Aidoni; Charilaos Koulouris; Efstathios Pavlidis; Dimitrios Giannakidis; Valeriu Surlin; Stelian Pantea; Victor Strambu; Rogoveanu Otilia Constantina; Aikaterini Amaniti; Paul Zarogoulidis; Stelian Mogoantă; Isaak Kesisoglou; Chrysanthi Sardeli
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

5.  Network Meta-Analysis of Efficacy and Safety of Chemotherapy and Target Therapy in the First-Line Setting of Advanced Pancreatic Cancer.

Authors:  Kun-I Lin; Jia-Lian Yang; Yu-Chao Lin; Che-Yi Chou; Jin-Hua Chen; Chin-Chuan Hung
Journal:  Cancers (Basel)       Date:  2019-11-07       Impact factor: 6.639

6.  Circulating Tumor Cells Expressing Krüppel-Like Factor 8 and Vimentin as Predictors of Poor Prognosis in Pancreatic Cancer Patients.

Authors:  Peng Zhu; Hui-Ying Liu; Fu-Chen Liu; Fang-Ming Gu; Sheng-Xian Yuan; Jian Huang; Ze-Ya Pan; Wei-Jun Wang
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

7.  An In Vitro Investigation into Cryoablation and Adjunctive Cryoablation/Chemotherapy Combination Therapy for the Treatment of Pancreatic Cancer Using the PANC-1 Cell Line.

Authors:  John M Baust; Kimberly L Santucci; Robert G Van Buskirk; Isaac Raijman; William E Fisher; John G Baust; Kristi K Snyder
Journal:  Biomedicines       Date:  2022-02-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.